Ivermectin as a Potential Therapeutic Agent for COVID-19 – case studies


  • Natalia Sisca Wijaya Mitra Kemayoran Hospital, Jakarta, Indonesia
  • Sidharta Salim Mitra Kemayoran Hospital, Jakarta, Indonesia




Ivermectin, SARS-CoV-2, COVID-19


In December 2019, an outbreak of a novel coronavirus (SARS-CoV-2) started in Wuhan, China, and has since become a global threat to human health. To date, the worldwide response to the COVID-19 outbreak has been limited mainly to monitoring/containment. Several types of drug, as well as vaccination, are still under investigation and clinical trials worldwide. Recently, a study demonstrated ~5000-fold reduction in SARSCoV-2 virus at 48h in cell culture after a single treatment of ivermectin. A clinical study at the University of Utah found that the administration of ivermectin during COVID-19 illness in hospitalized patients is associated with lower mortality and hospital length of stay. We report three confirmed cases of COVID-19 infection with significant improvement clinically and radiologically, with following treatment single dose of ivermectin.


Pada Desember 2019, wabah yang disebabkan oleh varian baru coronavirus (SARS-CoV-2) dimulai di Wuhan, China, dan saat ini telah menjadi ancaman global bagi kesehatan manusia. Hingga saat ini, respons dunia terhadap wabah COVID-19 masih terbatas pada pemantauan dan isolasi. Di seluruh dunia, beberapa jenis obat dan juga vaksinasi masih menjalani tahap investigasi dan uji klinis. Baru-baru ini, sebuah studi mendemonstrasikan bahwa satu dosis ivermectin mampu mengurangi ~5000-kali kadar SARS-CoV-2 virus dalam 48 jam pada kultur sel. Sebuah uji klinis di Universitas di Utah juga membuktikan bahwa ivermectin terbukti menurunkan angka mortalitas dan juga lama perawatan pasien COVID-19 rawat inap. Kami melaporkan tiga pasien dengan konfirmasi positif COVID-19 yang menunjukkan kemajuan signifikan klinis dan radiologis setelah pengobatan dengan satu dosis ivermectin.


Download data is not yet available.


Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med [Internet]. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1

Cally L, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-COV-2 in vitro. Science Direct 2020; DOI:10.1016/j.antiviral.2020.104787.

Patel AN, Desai SS, Grainger DW. Mehra MR. Usefulness of ivermectin in COVID-19 illness. SSRN [Internet]. 2020 [cited 2020 May 8]. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3580524

Jaroslaw D, Gorovits N. COVID-19 alert. DLA Piper [Internet]. 2020 [cited 2020 May 8]. Available from: https://www.dlapiper.com/en/us/insights/publications/2020/04/therapies-for-covid19-what-is-in-the-pipeline/

Lundberg L, Pinkham C, Baer A, Amaya M, Narayanan A, Wagstaff KM, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis virus replication. Antivir. Res. 2013;100(3):662-72.

Õmura S, Crump A. The life and times of ivermectin - a success story. Nat Rev Microbiol. 2004;2:984-9. 10.1038/nrmicro1048

Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42:1122-33.




How to Cite

Wijaya, N. S., & Salim, S. (2020). Ivermectin as a Potential Therapeutic Agent for COVID-19 – case studies. Cermin Dunia Kedokteran, 47(5), 370–372. https://doi.org/10.55175/cdk.v47i5.382